S*BIO’s Novel JAK2 Inhibitor Pacritinib (SB1518) Effectively Reduces Splenomegaly in Myelofibrosis (MF) Patients

15-Dec-2011 - S*BIO Pte Ltd announced that results from a Phase 2 study demonstrated that its JAK2 inhibitor pacritinib (SB1518) effectively reduced splenomegaly in myelofibrosis (MF) patients, with minimal impact on existing cytopenias providing an important therapeutic niche in the treatment of MF. Results ...

S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)

27-Oct-2011 - S*BIO Pte Ltd announced plans to initiate a global Phase 3 clinical program of its novel JAK2 inhibitor pacritinib (SB1518), in the first half of 2012 to further demonstrate its activity and tolerability for the treatment of myelofibrosis (MF). The company is actively exploring partnering ...

Additional Data from Multiple Phase 1 and 2 Studies of S*BIO’s Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis

SB1518 Alleviates MF-Associated Splenomegaly and Shows No Myelosuppression and No Exacerbation of Cytopenias

07-Jun-2011 - S*BIO Pte Ltd announced that additional data from multiple Phase 1 and 2 clinical studies of its novel JAK2 inhibitor SB1518 further confirmed safety and efficacy for the treatment of patients with symptomatic myelofibrosis (MF) and enlarged spleens. In the studies, SB1518 alleviated ...

S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies

18-Apr-2011 - S*BIO Pte Ltd announced that it has dosed the first 10 patients in a Phase 2 clinical trial of its novel JAK2 inhibitor SB1518 in the U.S. and Canada for the treatment of advanced lymphoid malignancies. This multi-center, open-label, study is designed to primarily evaluate the efficacy and safety ...

Oral Multi-Kinase Inhibitor SB1317, Enters Phase 1 Clinical Trial in Advanced/Refractory Hematologic Malignancies

24-Nov-2010 - S*BIO Pte Ltd announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO’s oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies ...

S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase (HDAC) Inhibitor SB939

29-Sep-2010 - S*BIO Pte Ltd announced the initiation of a Phase 2 clinical trial of SB939, its novel orally-active HDAC inhibitor, in patients with recurrent or metastatic prostate cancer (HRPC). The trial is sponsored by the NCIC Clinical Trials Group and will be conducted at eight clinical sites in Canada. ...

S*BIO Announces US$5 Million Investment by Mitsui Ventures

24-Sep-2010 - S*BIO Pte Ltd announced a US$5 million investment by Mitsui Ventures that will support the continued development of S*BIO’s clinical programs. “Mitsui Ventures’ financing commitment reflects the international investment community’s strong interest in our track record in advancing multiple assets ...

S*BIO Completes Enrollment of Patients in Phase 2 Clinical Trials for its JAK2 Inhibitor SB1518

10-Jun-2010 - S*BIO Pte Ltd announced that it has completed enrollment of patients in two separate Phase 2 clinical trials for its potent and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the U.S. and Australia for the treatment of myelofibrosis (MF). These two multi-center, single-arm, ...

S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors

06-May-2010 - S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. announced the expansion of their development collaboration and option and license commercialization agreement for S*BIO’s novel JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively. The expanded agreement builds upon ...

S*BIO becomes Singapore's first biotech company to initiate clinical trial of novel anti-cancer drug

22-Jun-2007 - S*BIO Pte Ltd announced that it has become Singapore's first biotechnology company to initiate a Phase I clinical trial of a novel anti-cancer compound. The compound, SB939, belongs to a new class of targeted anti-cancer therapeutics called histone deacetylase (HDAC) inhibitors. SB939 is designed ...